Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) – Pipeline Review, H2 2017’, provides in depth analysis on Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Metabolic Disorders, Gastrointestinal and Central Nervous System under development targeting Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)

The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amgen Inc

ArQule Inc

AstraZeneca Plc

Blueprint Medicines Corp

Bristol-Myers Squibb Co

Eisai Co Ltd

Eli Lilly and Co

Genosco Inc

H3 Biomedicine Inc

Incyte Corp

Ionis Pharmaceuticals Inc

Johnson & Johnson

Merrimack Pharmaceuticals Inc

NGM Biopharmaceuticals Inc

Novartis AG

Principia Biopharma Inc

Tasly Pharmaceutical Group Co Ltd

Vichem Chemie Research Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) - Overview 8

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) - Therapeutics Development 9

Products under Development by Stage of Development 9

Products under Development by Therapy Area 10

Products under Development by Indication 11

Products under Development by Companies 14

Products under Development by Universities/Institutes 21

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) - Therapeutics Assessment 23

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) - Companies Involved in Therapeutics Development 29

Amgen Inc 29

ArQule Inc 29

AstraZeneca Plc 30

Blueprint Medicines Corp 30

Bristol-Myers Squibb Co 31

Eisai Co Ltd 31

Eli Lilly and Co 33

Genosco Inc 33

H3 Biomedicine Inc 34

Incyte Corp 34

Ionis Pharmaceuticals Inc 35

Johnson & Johnson 35

Merrimack Pharmaceuticals Inc 36

NGM Biopharmaceuticals Inc 36

Novartis AG 37

Principia Biopharma Inc 37

Tasly Pharmaceutical Group Co Ltd 38

Vichem Chemie Research Ltd 38

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) - Drug Profiles 40

ARQ-087 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

AZ-709 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

BLU-554 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

BLU-9931 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

BMS-986036 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

erdafitinib - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

ES-135 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

FGF-401 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Fusion Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Fusion Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

golvatinib tartrate + lenvatinib mesylate - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

H-3B6527 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

INCB-62079 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

infigratinib - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

IONIS-463588 - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

lenvatinib mesylate - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

LY-2874455 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

MM-161 - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

NGM-282 - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

PRN-1371 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

Small Molecules to Antagonize FGFR4 for Hepatocellular Carcinoma - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

Small Molecules to Inhibit Pan FGFR for Oncology - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

TSLB-1344 - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) - Dormant Products 93

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) - Discontinued Products 94

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC

2.7.10.1) - Product Development Milestones 95

Featured News & Press Releases 95

Oct 31, 2017: New Drug Application Of Anticancer Agent Lenvatinib For Hepatocellular Carcinoma Accepted In China 95

Oct 20, 2017: Bristol-Myers Squibb to Present New Data on its liver disease drug candidate BMS-986036 at The Liver Meeting 2017 95

Oct 19, 2017: NGM Bio Provides Update On NGM282 In NASH 96

Oct 10, 2017: H3 Biomedicine Granted Orphan Drug Designation of H3B-6527 for Treatment of Hepatocellular Carcinoma 98

Sep 29, 2017: Eisai Presents Results of Phase III Trial of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma in Oral Session at 20th CSCO Annual Meeting 98

Sep 27, 2017: Application for Additional Indication of Lenvima for Hepatocellular Carcinoma Accepted for Review by U.S. FDA 100

Sep 26, 2017: FDA Accepts Supplemental New Drug Application for Eisais Lenvatinib for the Treatment of Liver Cancer 101

Sep 19, 2017: Eisai Presents Results Of Phase III Clinical Study Of Lenvima (Lenvatinib) In Unresectable Hepatocellular Carcinoma At 11th ILCA Annual Conference 102

Sep 15, 2017: H3 Biomedicine to Present New Data on H3B-6527, an FGFR4 Inhibitor, at the 2017 International Liver Cancer Association Annual Meeting 103

Sep 11, 2017: Eisai Presents New Quality of Life Findings in Hepatocellular Carcinoma Patients from Lenvatinib Versus Sorafenib Study in Oral Session at ESMO Congress 104

Sep 11, 2017: Eisai Presents Results of Phase Ib/II Clinical Study of Lenvima in Combination With Pembrolizumab for Renal Cell Carcinoma in Oral Session at ESMO 2017 Congress 105

Sep 10, 2017: Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma 106

Sep 01, 2017: Eisai to Present 3 Abstracts on Lenvima at ESMO 2017 Congress 108

Sep 01, 2017: Eisai To Present Abstracts On Oncology Products And Pipeline At ESMO 2017 Congress 109

Aug 28, 2017: Lenvatinib Significantly Improved Overall Survival in Older Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer According to Results of Subanalysis of Phase 3 SELECT Trial 111

Appendix 113

Methodology 113

Coverage 113

Secondary Research 113

Primary Research 113

Expert Panel Validation 113

Contact Us 113

Disclaimer 114

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Indications, H2 2017 11

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 13

Number of Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 15

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 18

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 19

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 20

Number of Products under Investigation by Universities/Institutes, H2 2017 21

Products under Investigation by Universities/Institutes, H2 2017 22

Number of Products by Stage and Mechanism of Actions, H2 2017 24

Number of Products by Stage and Route of Administration, H2 2017 26

Number of Products by Stage and Molecule Type, H2 2017 28

Pipeline by Amgen Inc, H2 2017 29

Pipeline by ArQule Inc, H2 2017 30

Pipeline by AstraZeneca Plc, H2 2017 30

Pipeline by Blueprint Medicines Corp, H2 2017 31

Pipeline by Bristol-Myers Squibb Co, H2 2017 31

Pipeline by Eisai Co Ltd, H2 2017 32

Pipeline by Eli Lilly and Co, H2 2017 33

Pipeline by Genosco Inc, H2 2017 34

Pipeline by H3 Biomedicine Inc, H2 2017 34

Pipeline by Incyte Corp, H2 2017 35

Pipeline by Ionis Pharmaceuticals Inc, H2 2017 35

Pipeline by Johnson & Johnson, H2 2017 36

Pipeline by Merrimack Pharmaceuticals Inc, H2 2017 36

Pipeline by NGM Biopharmaceuticals Inc, H2 2017 37

Pipeline by Novartis AG, H2 2017 37

Pipeline by Principia Biopharma Inc, H2 2017 38

Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017 38

Pipeline by Vichem Chemie Research Ltd, H2 2017 39

Dormant Projects, H2 2017 93

Discontinued Products, H2 2017 94

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 9

Number of Products under Development by Therapy Areas, H2 2017 10

Number of Products under Development by Top 10 Indications, H2 2017 11

Number of Products by Mechanism of Actions, H2 2017 23

Number of Products by Stage and Mechanism of Actions, H2 2017 23

Number of Products by Routes of Administration, H2 2017 25

Number of Products by Stage and Routes of Administration, H2 2017 25

Number of Products by Molecule Types, H2 2017 27

Number of Products by Stage and Molecule Types, H2 2017 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports